Abbott has launched its neuromodulation business’ next-generation delivery system, which will be used to streamline the implantation process for electrodes used as part of its Proclaim™ DRG neurostimulation system. The new system is intended to streamline the procedure when doctors implant the system in patients who are suffering from complex
Abbott has announced that the U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) for its Coronary Intravascular Lithotripsy (IVL) System to evaluate the treatment of severe calcification in coronary arteries prior to stenting. The TECTONIC Coronary Artery Disease (CAD) Intravascular Lithotripsy (IVL) clinical trial will
Abbott has unveiled ‘Above the Bias’, a film highlighting how diabetes stigma impacts care and well-being. Misconceptions in media and social settings create emotional barriers, but positive support improves motivation. Abbott’s initiative aims to challenge biases and foster a more supportive environment. By raising awareness, the campaign promotes understanding and
Get notified about new articles
